Creative Bioscience Meratrim 1234 is an over the counter diet pill that falls in the category of supplements that use a single ingredient to produce a certain result. In this case, the formula is actually one patented and branded substance.
The ingredient in question is called Meratrim, which brings together two different plant extracts, garcinia mangostana fruit rind and sphaeranthus indicus flower. Meratrim doesn’t have very much scientific evidence to support its use, but it was once featured on the Dr. Oz Show and it rapidly skyrocketed into popularity simply because it was mentioned. The daytime television celebrity frequently has this effect on products and ingredients regardless of whether or not there is science to support their use.
Therefore, it’s a good idea to take a closer look at Creative Bioscience Meratrim 1234 before simply assuming it will be safe and effective. That way, you can make an informed decision. This effort begins with a trip to the doctor’s office. This is because a doctor will know whether or not the product is appropriate for your unique needs and expectations. Even a safe and effective product can be inappropriate for people with certain common conditions, who are taking other medications or who are taking supplements. As the ingredients in this product can lead to a hormonal shift, it should be taken very seriously.
That said, you can also conduct your own research by looking at the official website and at any studies that have been held on the individual ingredients of a formula or the combination as a whole.
The official webpage for Creative Bioscience Meratrim 1234 on the manufacturer’s website does point to a study conducted on the Meratrim ingredient. That research involved the participation of 57 people, half of whom used Meratrim supplementation and half of whom were in the control group. This small study ran for only 16 weeks.
While the results of that study did appear to be positive, it’s important to note that this is not a published study in a medical journal. The method for this study has not been revealed and the sample group is far too small to represent the general population. Moreover, the 16 week period is too short to know whether or not the substance is safe and effective.
Still, it does look promising. When Meratrim undergoes a larger, longer study and replicates the types of outcomes seen in that small preliminary research, it may be something worth taking more seriously.